Patients with eosinophilic granulomatosis with polyangiitis experienced significant improvements in a variety of outcomes ...

Mepolizumab, a humanized monoclonal antibody that targets interleukin-5 (IL-5), significantly reduced COPD exacerbations in patients with COPD regardless of the history or severity of ...

GSK has received approval from the US Food and Drug Administration (FDA) for its monoclonal antibody, Nucala (mepolizumab).

SAN FRANCISCO — Patients with COPD and type 2 inflammation receiving mepolizumab vs. placebo had decreased moderate and severe exacerbation rates and fewer ED visits per exacerbation at 104 ...

Mepolizumab is the only approved biologic evaluated in patients with an eosinophilic phenotype characterized by a blood eosinophil count (BEC) threshold as low as ≥150 cells/µL. 1,2 BEC is ...

FDA approves mepolizumab (Nucala; GSK) as the first monthly biologic for chronic obstructive pulmonary disease (COPD), significantly reducing exacerbations in patients with an eosinophilic phenotype.

The phase 3 MATINEE trial (NCT04133909) provided additional context for where mepolizumab may be most useful. 2 This trial randomized 804 patients with a history of frequent exacerbations and ...

The study evaluated 807 adults who initiated an anti–IL–5 therapy (79% mepolizumab, 21% benralizumab) between 2017 and 2020. Among them, 191 patients had diagnoses of both asthma and COPD.

The researchers found that the annualized rate of moderate or severe exacerbations was significantly lower with mepolizumab than placebo (0.80 vs 1.01 events per year; rate ratio, 0.79).

Mepolizumab is a humanized monoclonal antibody that targets interleukin-5, a cytokine that plays a central role in eosinophilic inflammation, which is present in 20 to 40% of patients with chronic ...